BNP Paribas Financial Markets Grows Holdings in InfuSystem Holdings, Inc. (NYSE:INFU)

BNP Paribas Financial Markets grew its stake in shares of InfuSystem Holdings, Inc. (NYSE:INFU) by 66.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,076 shares of the company’s stock after buying an additional 1,626 shares during the quarter. BNP Paribas Financial Markets’ holdings in InfuSystem were worth $27,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. First Eagle Investment Management LLC lifted its holdings in shares of InfuSystem by 10.0% in the 2nd quarter. First Eagle Investment Management LLC now owns 666,048 shares of the company’s stock worth $4,549,000 after acquiring an additional 60,813 shares during the last quarter. Greenwood Capital Associates LLC grew its stake in shares of InfuSystem by 14.0% in the third quarter. Greenwood Capital Associates LLC now owns 119,062 shares of the company’s stock worth $798,000 after purchasing an additional 14,587 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of InfuSystem by 6.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 93,899 shares of the company’s stock worth $641,000 after buying an additional 5,391 shares during the last quarter. Kings Path Partners LLC purchased a new position in shares of InfuSystem during the second quarter valued at approximately $514,000. Finally, GSA Capital Partners LLP raised its holdings in InfuSystem by 23.9% in the 3rd quarter. GSA Capital Partners LLP now owns 65,680 shares of the company’s stock worth $440,000 after purchasing an additional 12,657 shares in the last quarter. 71.13% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on INFU. StockNews.com raised shares of InfuSystem from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 8th. B. Riley started coverage on shares of InfuSystem in a research note on Thursday, September 26th. They set a “buy” rating and a $13.00 price objective for the company.

Insider Buying and Selling at InfuSystem

In other InfuSystem news, CEO Richard Dilorio sold 5,398 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $8.87, for a total value of $47,880.26. Following the completion of the transaction, the chief executive officer now directly owns 416,659 shares in the company, valued at $3,695,765.33. This represents a 1.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 10.20% of the company’s stock.

InfuSystem Price Performance

INFU stock opened at $8.31 on Friday. The stock has a market cap of $176.70 million, a P/E ratio of 138.52 and a beta of 1.53. The company has a current ratio of 1.98, a quick ratio of 1.59 and a debt-to-equity ratio of 0.50. InfuSystem Holdings, Inc. has a 1 year low of $5.74 and a 1 year high of $10.89. The business has a fifty day moving average price of $8.05.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.